Unity biotechnology, inc. (UBX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
Operating activities
Net loss

-82,177

-76,398

-44,656

-30,404

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,663

2,180

1,304

153

Net accretion and amortization of premium and discounts on marketable securities

1,151

955

-182

-

Stock-based compensation

10,852

9,441

3,034

224

Loss on extinguishment of promissory notes

-

-

-

-9,377

Non-cash interest expense

-

-

-

2,223

Loss on disposal of property and equipment

-

45

15

-

Common stock granted to third party

965

-

44

447

Change in fair value of strategic investment

4,507

-

-

-

Accretion of tenant improvement allowance

1,275

605

605

403

Change in fair value of contingent consideration for license agreements

-1,352

4,542

-

-

Changes in operating assets and liabilities:
Contribution receivable

-

-1,382

1,382

-

Prepaid expenses and other current assets

169

842

746

229

Other long-term assets

31

604

-23

41

Accounts payable

-227

2,228

1,198

198

Accrued compensation

2,114

1,610

1,607

504

Accrued and other current liabilities

-587

1,446

1,258

1,046

Deferred rent, net of current portion

2,461

-93

366

27

Other non-current liabilities

-

-

-

480

Net cash used in operating activities

-72,421

-56,623

-38,358

-16,398

Investing activities
Purchase of marketable securities

119,270

204,086

134,465

-

Maturities of marketable securities

188,809

133,644

49,849

-

Purchase of investment in stock

-

500

-

500

Purchase of property and equipment

1,586

1,264

1,689

2,244

Net cash provided by investing activities

67,953

-72,206

-86,305

-2,744

Financing activities
Proceeds from issuance of common stock under ATM Offering Program, net of issuance costs

26,085

-

-

-

Proceeds from issuance of convertible promissory notes payable

-

-

-

16,887

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

59,881

42,867

90,956

Proceeds from issuance of common stock upon exercise of stock options, net of repurchases

840

374

-37

95

Proceeds from issuance of common stock under ESPP

586

-

-

-

Proceeds from initial public offering, net of issuance costs

-

79,055

-

-

Payment of initial public offering costs

-

3,201

-

-

Proceeds from repayment of recourse notes

-

895

-

-

Payments made on capital lease obligations

73

74

55

-

Net cash provided by financing activities

27,438

136,930

42,775

107,938

Net increase (decrease) in cash, cash equivalents and restricted cash

22,970

8,101

-81,888

-

Net increase in cash, cash equivalents and restricted cash

-

-

-

88,796

Supplemental Disclosures of Non-Cash Investing and Financing Activities
Conversion and settlement of convertible notes and accrued interest into convertible preferred stock

-

-

-

15,667

Property and equipment included in accounts payable and accrued liabilities

565

241

314

98

Property and equipment acquired under capital leases

-

-

243

-

Lessor funded lease incentives included in property and equipment

10,651

-

3,881

-

Receipt of promissory note for purchase of common stock

-

400

-

-

Receipt of promissory note from related party for purchase of common stock

27

390

-

153